Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program

•There were no new safety concerns with longer exposure to ozanimod.•Hepatic enzyme elevations were typically asymptomatic and transient.•Macular edema was rare (≤0.4%) and associated with predisposing comorbidities.•7% had ALC

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders 2021-06, Vol.51, p.102844-102844, Article 102844
Hauptverfasser: Selmaj, Krzysztof W., Cohen, Jeffrey A, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans Peter, Montalban, Xavier, Havrdova, Eva Kubala, Cree, Bruce A.C., Minton, Neil, Sheffield, James K, Ding, Ning, Kappos, Ludwig
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Clinical trials
Multiple sclerosis
Ozanimod
Safety
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•There were no new safety concerns with longer exposure to ozanimod.•Hepatic enzyme elevations were typically asymptomatic and transient.•Macular edema was rare (≤0.4%) and associated with predisposing comorbidities.•7% had ALC
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2021.102844